Hans Schikan

Hans Schikan brings more than 30 years of development, commercial and leadership experience in the (bio)pharmaceutical sector, latest as CEO of Prosensa in The Netherlands, a company focusing on rare diseases, with a lead program in Duchenne Muscular Dystrophy. During Mr. Schikan’s leadership, Prosensa established a collaboration with GlaxoSmithKline in 2009 and was listed on NASDAQ in a successful IPO in June 2013. The company was acquired by BioMarin early 2015 for up to USD 840 million.

Mr. Schikan’s previous assignments include Vice President, Marketing and Strategic Development for the rare disease portfolio of Genzyme and several senior commercial roles in Organon. He served on the boards of Wilson Therapeutics (acquired by Alexion in 2018) and Therachon (acquired by Pfizer in 2019).

Currently he serves on the board of a number of public and private biotech companies in The Netherlands, Belgium, Sweden, Switzerland and the United Kingdom. He is member of the core team of the Dutch Top Sector for Life Sciences & Health. Finally, he is co-founder of Pharvaris, listed on NASDAQ, which develops an oral compound for the rare disease HAE.